News
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline
Release Date: 21 December 2023
ImmuMab Heavy® mice are able to produce fully human antibodies, consisting solely of heavy chains, without the presence of light chains. These mice possess over 120 human immunoglobulin heavy-chain V genes at the mouse immunoglobulin gene loci, thanks to the parental strain ImmuMab® mice.
Immunocan pioneers Mb gene replacement technology to create a new fully human antibody mouse platform
Release Date: 03 December 2022
Along with the continuous development of antibody-based drug technology, monoclonal antibody drugs and innovative therapeutics based on monoclonal antibodies (bispecific antibody,
ImmuMab® mice generated Consistent and Stable Immune Responses as Wild-type Mice-Immunocan accelerating development of fully human antibodies
Release Date: 12 April 2023
In December 2022, Shanghai Immunocan Biotech Co., Ltd. launched ImmuMab® mouse, a fully human antibody discovery platform based on patented gene editing technology, and initiated mouse evaluation and application projects. Thus far, the four projects from different antigens have demonstrated stable immune responses as wild type mice, laying a solid foundation for further development of therapeutic antibodies.
Immunocan raised 50 million RMB in pre-A financing, led by Kingray Capital
Release Date: 16 August 2021
On August 16th, according to the report from the investment community, Shanghai Immunocan Biotech Co. (hereinafter referred to as “Immunocan”), a fully human antibody drug development company, has completed a Pre-A round of financing of RMB 50 million recently.